Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | KRAS | P01116 | 5/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | CDK14 | O94921 | 1/20 | 0.34 |
| ▸ | CCNY | Q8ND76 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634311 | 0.86 | HTR6 (0.41) | HTR6TRPV1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL17634298 | 0.80 | CKS1B (0.45) | KIT | |
| SCHEMBL28587642 | 0.78 | POLB (0.44) | HTR6PIK3CDPIK3CAPIK3CB | |
| SCHEMBL17640810 | 0.77 | KRAS (0.61) | KRAS | |
| SCHEMBL17640816 | 0.77 | KRAS (0.44) | JAK3KRASTRPV1 | |
| SCHEMBL26683753 | 0.65 | DRD2 (0.47) | HTR6KIT | |
| SCHEMBL14553409 | 0.65 | NOS1 (0.52) | — | |
| SCHEMBL31148280 | 0.65 | NOS1 (0.52) | — | |
| SCHEMBL30125124 | 0.64 | NOS1 (0.41) | BTK | |
| SCHEMBL17640836 | 0.64 | KRAS (0.57) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| EP-3197870-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| WO-2016049524-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049524-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | JAK3 3314/4885KRAS 1/4885HTR6 4832/4885 |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | JAK3 3314/4885KRAS 1/4885HTR6 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.